Sanofi defends top oncology drug with Jevtana patent win

Sanofi has been battling against generics companies over patents to Jevtana, its top oncology product. In the latest round, the company scored a win to defend a 2021 patent and a 2031 patent. The company convinced an appeals court to overturn a prior loss it suffered on a 2031 patent.